From cystogenesis to carcinogenesis in ADPKD: risk modeling and a multistep precision surveillance Authors: Angeliki Margoni, Kostas A Papavassiliou, Athanasios G Papavassiliou Published: 2026 Clinical monitoring of autosomal dominant polycystic kidney disease (ADPKD) has traditionally focused on predicting progression to end stage renal disease (ESRD) based on estimated glomerular filtration rate (eGFR) and serial imaging with total kidney volume (TKV) quantification. ADPKD, the leading monogenic cause of ESRD, affects approximately 1 in 1,000 individuals and confers to a 1.6 to 3.2-fold relative mortality rate compared to general population [1–3]. Emerging epidemiological data suggests that ADPKD is also associated with an approximately two-fold increased risk of renal cell carcinoma (RCC) [1–6]. Nevertheless, this epidemiological signal should be interpreted with caution. The reported excess RCC risk in ADPKD derives from heterogeneous observational datasets, with variability in study design, population selection, renal function stage, nephrectomy status, and imaging intensity. Moreover, RCC cases reported in ADPKD include different histological subtypes, and increased radiological surveillance of cystic kidneys may inflate detection rates compared with the general population. Therefore, the approximately two-fold risk estimate should be viewed as a clinically relevant but not yet definitive signal, requiring prospective, systematically imaged cohorts to clarify true RCC incidence and risk determinants in ADPKD [1–6]. Although direct evidence remains limited, malignant transformation within chronically proliferative cystic epithelium provides biological plausibility rather than definitive evidence of a direct cyst-to-carcinoma sequence [1, 3]. Molecular advancements have delineated pathways through which progressive cyst expansion promotes chronic hypoxia, inflammation, and fibrotic remodeling of the renal parenchyma, thereby establishing a pro-tumorigenic microenvironment [1–3]. At the cellular level, loss of functional polycystins disrupts primary cilium-mediated mechanosensing, leading to aberrant intracellular calcium signaling, cyclic AMP (cAMP) accumulation, and sustained activation of proliferative cascades including mechanistic target of rapamycin (mTOR), mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), and Wnt/β-catenin pathways [1, 7, 8]. These signaling perturbations primarily drive cystogenesis but also involve canonical pathways implicated in renal tumor biology, including mTOR, MAPK/ERK, and Wnt/β-catenin signaling [4, 7–11]. While activation of these pathways is not specific to malignant transformation, their convergence supports a shared molecular framework that may contribute to both cystic remodeling and tumor development. Emerging evidence further implicates the von Hippel–Lindau (VHL) pathway in this mechanistic continuum. Beyond its canonical regulation of hypoxia-inducible factors (HIFs), VHL contributes to primary cilium maintenance and epithelial polarity, suggesting that disruption of ciliary homeostasis may converge with hypoxia signaling to facilitate both cyst progression and renal tumorigenesis [7, 9, 10]. Moreover, metabolic reprogramming characterized by enhanced glycolysis and mitochondrial dysfunction—features reminiscent of the Warburg effect—has been increasingly recognized in cystic epithelial cells. Although enhanced glycolysis represents a common adaptive response to cellular stress and is not specific to neoplastic transformation, these metabolic alterations further support mechanistic parallels between cystic remodeling and tumor biology [7–11]. In parallel, the cystic microenvironment evolves toward a hypoxic and inflammatory niche, where hypoxia-inducible factors (HIFs), oxidative stress, and macrophage infiltration collectively promote genomic instability, epithelial dedifferentiation, and angiogenesis—hallmarks of early carcinogenesis [8, 9]. Importantly, crosstalk between cyst-lining epithelial cells and the surrounding extracellular matrix (ECM), mediated by matricellular proteins (MPs) and fibrotic signaling such as transforming growth factor beta (TGF-β), creates a permissive stromal scaffold that may facilitate malignant transformation [9, 12]. Another emerging mechanistic link involves dysregulated mechanistic target of rapamycin complex 1 (mTORC1) signaling and downstream activation of transcription factor E3 (TFE3). Persistent mTORC1 dysregulation may promote nuclear TFE3 translocation, altering lysosomal biogenesis, autophagy, cellular metabolism, and proliferative transcriptional programs that are increasingly recognized as shared features of cystic remodeling and renal carcinogenesis [7–11]. Reconceptualizing surveillance in ADPKD through an integrated framework that combines clinical parameters, quantitative imaging, genotyping, and molecular biomarkers may capture early manifestations of oncogenesis and translate molecular insights into novel therapeutic strategies, further advancing both nephrology and renal oncology. Next generation sequencing (NGS)-based panels for ADPKD are increasingly adopted, yet important technical constraints persist in ADPKD genotyping, exposing an important translational burden as clinical surveillance has remained remarkably conservative [13, 14]. Although historically the clinical utility of genotyping was hindered by high costs and technical barriers, the convergence of NGS and state-of-the-art bioinformatics tools enables deep genomic interrogation and molecular stratification of patients into low-, intermediate-, and high-risk trajectories, thereby enhancing prognostic precision, monitoring, and timely personalized interventions. Genetic profiling is pivotal in ADPKD risk assessment, as polycystic kidney disease 1 (PKD1; encoding polycystin-1 (PC-1), an 11-transmembrane domain-containing protein involved in cell−to−cell interactions and renal tubulogenesis) and polycystic kidney disease 2 (PKD2; encoding polycystin-2 (PC-2), a transient receptor potential (TRP) cation channel that regulates intracellular calcium homeostasis) gene variants differ in prevalence, molecular pathways, and clinical prognosis [1, 2, 4–6, 13, 14]. Specifically, mutations in PKD1, responsible for 80–85% of cases, disrupt PC-1-mediated proliferative pathways such as mTOR and MAPK signaling cascades, leading to more aggressive cyst growth and earlier progression to ESRD [1, 3, 13]. Clinically, PKD1 mutation carriers more frequently exhibit early hypertension, accelerated cyst expansion, greater kidney enlargement, and elevated susceptibility to RCC. In contrast, PKD2 mutations (accounting for ~ 15% of cases) impair PC-2-dependent calcium signaling, producing a milder phenotype, less susceptible to RCC. PKD2 carriers exhibit late onset of hypertension, slower cyst expansion and kidney enlargement, and relative slow renal function decline leading to late-onset ESRD [1, 3, 4]. Importantly, despite its transformative impact, NGS remains challenged in PKD1 due to gene size, high GC content, and extensive homology with pseudogenes, while even PKD2 may evade detection of structural rearrangements. Consequently, a negative NGS result should not be equated with absence of genetic causation but interpreted considering these methodological limitations [13]. Beyond PKD1 and PKD2, emerging evidence suggests that modifier genes, epigenetic alterations, and somatic “second-hit” mutations within cyst epithelium may further influence both disease severity and oncogenic potential [4, 7, 12, 15, 16]. Clonal expansion of epithelial cells harboring additional genomic alterations may represent a critical transition point linking benign cyst growth to dysplastic and neoplastic evolution. Integrating germline and somatic genomic data could therefore refine individualized cancer risk prediction models in ADPKD. Nonetheless, PKD1/PKD2 genotyping alone, cannot fully explain the clinical heterogeneity of ADPKD, or its potential tumorigenic implications. Likewise, height-adjusted total kidney volume (ht-TKV) assessed by ultrasound or preferably magnetic resonance imaging (MRI) is a validated predictor of disease progression but primarily captures late structural changes [1–3, 13]. Consequently, multiplex panels integrating highly informative biomarkers are essential for early detection of RCC risk and disease progression. Biomarkers including urinary kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), monocyte chemoattractant protein-1 (MCP-1), urinary angiotensinogen (uAGT), copeptin, serum uric acid, cystatin C, TGF-β, periostin, and MPs collectively capture key pathophysiological domains preceding structural deterioration or malignant transformation [2, 7, 9, 12–15] (Table 1). MCP-1 and NGAL reflect inflammation and cyst-related tubular stress, TGF-β and periostin indicate fibrotic remodeling, whereas MPs further characterize a pro-tumorigenic ECM milieu. Furthermore, markers such as KIM-1, uAGT, copeptin, cystatin C, serum uric acid, and ht-TKV depict tubular injury, intrarenal renin–angiotensin system (RAS) activation, vasopressin-driven cystogenesis, and early functional decline [1, 2, 6, 13–15] (Table 1). Notably, several of these biomarkers have also been implicated in oncogenic pathways. For example, KIM-1 expression has been associated with renal epithelial dedifferentiation and tumor progression, while NGAL participates in matrix remodeling and metastatic signaling. Similarly, elevated TGF-β and periostin levels contribute to epithelial–mesenchymal transition (EMT), a critical step in carcinogenesis [11–12]. This dual role underscores their potential utility as convergent biomarkers bridging cyst progression and oncogenic transformation. Importantly, the biomarkers summarized in Table 1 differ substantially in their level of clinical validation. Whereas ht-TKV and selected clinical parameters are incorporated into current ADPKD risk stratification, most molecular biomarkers remain investigational, with variable prospective validation, assay standardization, and availability in routine clinical practice [2, 12, 13, 16]. Furthermore, several biomarkers capture overlapping biological processes, including inflammation, tubular injury, and fibrosis, and should therefore be regarded as complementary components of future multiplex surveillance panels rather than independent diagnostic tools. Table 1From imaging to biomarkers: redefining precision surveillance and RCC risk prediction in ADPKDBiomarkerMolecular / functional effectClinical impactPrognostic valuePKD1 mutationsDisruption of PC‑1 signaling activating mTOR and MAPK pathwaysAccelerated cyst expansion, earlier hypertension, larger TKV, earlier ESRD, increased RCC susceptibilityHigh‑risk ADPKD trajectory requiring intensified surveillancePKD2 mutationsImpaired PC‑2 calcium signaling affecting tubular homeostasisMilder cystic disease and slower functional declineLower‑risk disease course relative to PKD1 mutationsht-TKVQuantitative imaging marker of cumulative cyst burden and structural remodelingPredictor of renal function decline and rapid disease progressionValidated imaging criteria through MRI (preferable) for risk stratification based on Mayo Imaging ClassificationKIM‑1Marker of proximal tubular epithelial injury and regeneration. Epithelial dedifferentiation and tumor-associated pathwaysSignals early tubular damage and possible premalignant epithelial stressCandidate biomarker for early oncogenic or injury‑related changesNGALReleased during tubular stress and inflammatory activation. Matrix remodeling and tumor progressionDetects early renal injury and inflammationEarly indicator preceding structural deteriorationMCP‑1Chemokine recruiting monocytes/macrophages and mediating inflammationAssociated with cyst growth and inflammatory microenvironmentMarker of active inflammatory disease progressionuAGTReflects intrarenal RAS activationAssociated with hypertension, cyst expansion, and renal injuryIndicator of RAS‑driven disease activityCopeptinStable surrogate of vasopressin signaling regulating cyst growthElevated levels correlate with accelerated ADPKD progressionIdentifies patients who may benefit from vasopressin‑targeted therapySerum uric acidAssociated with oxidative stress and metabolic dysregulationLinked to renal injury progression and fibrosisMetabolic marker of adverse renal outcomesCystatin CGlomerular filtration marker independent of muscle massDetects early renal impairment missed by creatinineImproves sensitivity of renal function monitoringTGF‑βCentral mediator of fibrosis, ECM deposition, and EMTPromotes fibrotic remodeling and tumor‑permissive microenvironmentBiomarker of fibrotic progressionPeriostinExtracellular matrix protein involved in tissue remodeling, tumor stromal remodeling, and EMTReflects progressive structural remodelingIndicator of advanced fibrosis; index for antifibrotic targeted therapyMPsRegulate cell–matrix interactions and extracellular matrix dynamicsSupport tissue remodeling and tumor‑permissive environmentCandidate markers of oncogenic microenvironmental changeADPKD: autosomal dominant polycystic kidney disease; ECM: extracellular matrix; eGFR: estimated glomerular filtration rate; EMT: epithelial–mesenchymal transition; ESRD: end-stage renal disease; ht-TKV: height-adjusted total kidney volume; KIM-1: kidney injury molecule-1; MAPK: mitogen-activated protein kinase; MCP-1: monocyte chemoattractant protein-1; MPs: matricellular proteins; mTOR: mechanistic target of rapamycin; NGAL: neutrophil gelatinase-associated lipocalin; PC-1: polycystin-1; PC-2: polycystin-2; PKD1: polycystic kidney disease 1 gene; PKD2: polycystic kidney disease 2 gene; RAS: renin–angiotensin system; RCC: renal cell carcinoma; TGF-β: transforming growth factor-beta; TKV: total kidney volume; uAGT: urinary angiotensinogen From imaging to biomarkers: redefining precision surveillance and RCC risk prediction in ADPKD ADPKD: autosomal dominant polycystic kidney disease; ECM: extracellular matrix; eGFR: estimated glomerular filtration rate; EMT: epithelial–mesenchymal transition; ESRD: end-stage renal disease; ht-TKV: height-adjusted total kidney volume; KIM-1: kidney injury molecule-1; MAPK: mitogen-activated protein kinase; MCP-1: monocyte chemoattractant protein-1; MPs: matricellular proteins; mTOR: mechanistic target of rapamycin; NGAL: neutrophil gelatinase-associated lipocalin; PC-1: polycystin-1; PC-2: polycystin-2; PKD1: polycystic kidney disease 1 gene; PKD2: polycystic kidney disease 2 gene; RAS: renin–angiotensin system; RCC: renal cell carcinoma; TGF-β: transforming growth factor-beta; TKV: total kidney volume; uAGT: urinary angiotensinogen Beyond ESRD and RCC prediction, periostin and copeptin may further enable precision therapy by targeting vasopressin signaling and profibrotic pathways with innovative regimens, introducing the benefits of precision medicine [1, 2, 9]. However, robust validation is required to identify biomarkers with optimal sensitivity, specificity, and clinical utility. Prospective longitudinal studies should define their interaction with genotype and imaging metrics in predicting oncogenic risk. Herein, we propose a stepwise, precision-oriented monitoring strategy that begins with an upgraded baseline routine urinalysis and serial measurement of ht-TKV. In practice, baseline evaluation should be performed at diagnosis and include genotyping, ht-TKV, routine renal function assessment supplemented by cystatin C, and selected molecular biomarkers. Patients with PKD1 mutations, rapidly increasing ht-TKV, accelerated renal function decline, or persistently abnormal biomarker profiles may undergo more frequent imaging and biomarker reassessment, whereas lower-risk individuals may continue standard follow-up. Although precise surveillance intervals remain to be established, such risk-adapted escalation provides a pragmatic framework until prospective studies define evidence-based thresholds. Refining renal function surveillance, by incorporating cystatin C into routine assessment, is vital for early diagnosis of glomerular impairment, because creatinine-based eGFR may underestimate functional decline in patients with substantial cyst burden [8]. Additionally, expanded molecular biomarker testing is crucial in high-risk groups—males, PKD1 mutation carriers, and ESRD patients—to align surveillance intensity with biological risk and augment the benefits of prevention and evidence-based therapeutic management [2, 9]. The increased susceptibility observed in males may reflect the combined influence of sex hormones, greater cumulative kidney volume and disease severity, and sex-related differences in inflammatory and proliferative signaling, although the underlying mechanisms remain incompletely understood [2, 9]. Collectively, integrating these multidimensional data streams through predictive models may enable dynamic, individualized risk scores that evolve over time, incorporating genotype, longitudinal imaging trajectories, and biomarker kinetics [10, 11, 14, 16–18]. To clarify the intended scope, we emphasize that risk modeling refers to a conceptual framework for integrating multidimensional clinical, imaging, genetic, and molecular data to support individualized risk stratification, rather than to a validated quantitative prediction model. Furthermore, emerging liquid biopsy platforms—including circulating tumor DNA (ctDNA) and extracellular vesicles (EVs)—represent promising future tools for less-invasive detection of malignant transformation in ADPKD populations, potentially preceding clinical or radiologic evidence [6, 10, 16–18]. However, their clinical application remains investigational, as limited sensitivity in early-stage RCC and the need for analytical standardization currently preclude routine implementation [6, 10, 11, 16–18]. Taken together, such a multilayered, risk-adapted ADPKD monitoring model that incorporates clinical, imaging, genetic, and multiplex biomarker data—supported by advanced bioinformatics—could identify early deviations toward oncogenic pathways and trigger intensified imaging surveillance or targeted interventions. These advances support a transition toward an omics-based surveillance paradigm, thereby promising a shift from reactive surveillance toward anticipatory, precision-guided care and oncologic vigilance.